Swedish Orphan Biovitrum AB (publ) banner
Financial profile · Q3 FY2026

Growing specialty-medicine portfolio with profitable operations and lumpy cash conversion

Sobi’s multi-year statements show expanding revenue, profitable operations, and recurring operating cash generation, while working-capital demands and episodic investment spending make free cash flow more variable. Large acquired-intangible impairments can also make reported earnings less comparable from period to period.

What is developing

The latest results continued portfolio growth and showed a rebound in reported earnings against a prior-year impairment, while working-capital outflows tempered cash conversion. This is a meaningful movement in reported results, but not evidence that the underlying financial model has changed.

What matters next

Whether inventory and receivables stop absorbing cash and operating cash flow tracks the continued earnings growth.

SEK
Metric FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
5.2B 6.5B 9.1B 14.2B 15.3B 15.5B 18.8B 22.1B 26B 28.2B
(1.6B) (1.9B) (2.4B) (3.3B) (3.2B) (3.5B) (4.4B) (5B) (5.7B) (6B)
3.7B 4.7B 6.7B 10.9B 12B 12B 14.4B 17.2B 20.3B 22.3B
(2.5B) (3B) (3.6B) (6.4B) (7.6B) (8.3B) (9.9B) (12.5B) (14.5B) (14.2B)
(1.4B) (1.6B) (2B) (3.5B) (4B) (4.3B) (5.4B) (6.7B) (7.3B) (7.5B)
R&D
(778m) (901.7m) (1.1B) (1.5B) (1.6B) (2B) (2.2B) (2.7B) (3.5B) (3.2B)
(410m) (459.6m) (471.8m) (1.5B) (2B) (2B) (2.2B) (3.1B) (3.7B) (3.5B)
37m 264k 6.1m 17m 2m 30m 33m 10m 8m 9m
1.1B 1.7B 3.1B 4.5B 4.5B 3.8B 4.5B 4.7B 5.8B 8.1B
(85m) (118.7m) (39.5m) (268m) (610m) (401m) (497m) (1.2B) (1.2B) (862m)
— 64m 56.5m 241m 454m 419m 458m 1.1B 1.2B 802m
— — (4m) 34m 397m (56m) (675m) (496m) (197m) (7.1B)
— (1.8m) (3.2m) (19m) (33m) (35m) (28m) (51m) (59m) (26m)
1B 1.5B 3.1B 4.2B 4.2B 3.3B 3.3B 3B 4.4B 34m
(247m) (383.8m) (663.9m) (942m) (972m) (616m) (683m) (546m) (528m) 442m
801m 1.1B 2.4B 3.3B 3.2B 2.7B 2.6B 2.4B 3.9B 476m
— — — — — — — — 6m 2m
801m 1.1B 2.4B 3.3B 3.2B 2.7B 2.6B 2.4B 3.9B 478m
2.98 4.25 8.93 11.22 10.41 8.62 8.44 7.39 11.24 1.38